BioMimetic Therapeutics  

Company News

FDA rejection of Augment graft improves future for smaller companies (August 12, 2013)
Medtech M&A on course for the worst year in a decade (July 25, 2013)

Displaying 10 out of a possible 225 unique stories.
Results Sorted By date

EvaluatePharma® - the premier source for pharma and biotech analysis.

Expert integration of financial and product data across historic and forecast timeframes (1986 to 2018) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status, deals, license revenues and much more.

Company Profile

Profile 01 MAR 2013: Wright Medical Group acquired BioMimetic Therapeutics for $380m or $12.97 per share, based on Wright’s closing stock price on 16 NOV 2012.

BioMimetic Therapeutics (BMTI) was a Tennessee based biotechnology company focused on development & marketing of clinically proven products to promote the healing of musculoskeletal injuries & diseases, including therapies for orthopaedic & sports medicine applications.
Listed or Private Company Listed
Company Classification Specialty (Pharma); Biotechnology; MedTech
Country USA
Company Website
Technology Platform Profile Regenerative technology:
Promotes tissue healing and regeneration by combining rhPDGF-BB with tissue specific matrices, when appropriate.
Full Company Profile Information

EventAnalyzer - Last Key Event

Closing Price DateClosing Price Date EventAnalyzer Note Market Cap (US $m) Change (%) Change (+$m)
19/11/2012 19 Nov: Wright Medical plans to buy company for $190m in cash and stock, plus an additional $190m if the FDA approves BioMimetic's Augment Bone Graft and if products reach certain sales targets; deal completion due Q1'13. Loewen Ondaatje McCutcheon maintains "buy" rating with a price target of $7.50. 204 74.2% 87

EvaluatePharma® Coverage of Marketed and Pipeline Products

Product Count
BioMimetic Therapeutics 1 12


Evaluate provides market intelligence and analysis for the pharma, biotech and medtech industries.

Explore Evaluate


EvaluatePharma® now includes Partnering Opportunities - products available for licensing.

Partnering Opportunities in EvaluatePharma® are sourced from the rights holders - all entries are verified by the team of Analysts at EvaluatePharma - and presented in their commercial context.

Register to submit your Partnering Opportunities or to see your own and other Partnering Opportunities in their commercial context with the unique industry-wide analysis in EvaluatePharma®.

Take a full subscription to see all products available for license, including updated contact details for the out-licensing entity.

Register to access more FREE content:

  • 2011 Product Sales analysis
  • 2011 Pharmaceutical Sales
  • 2011 Market Share & Global Ranking
  • Download to Excel
  • Search 2 yrs of company press releases

Register for Free Analysis

Register to access more free insights and analysis from Evaluate.

Register Now